Advances in Lipid-Based Codelivery Systems for Cancer and Inflammatory Diseases

Chinmay M. Jogdeo, Sudipta Panja, Shrey Kanvinde, Ekta Kapoor, Kasturi Siddhanta, David Oupický

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of drug delivery that aims to achieve combined delivery of diverse therapeutic cargoes within the same delivery system, thereby ensuring delivery to the same site and providing an opportunity to tailor the release kinetics as desired. Among the wide range of materials being investigated in the design of codelivery systems, lipids have stood out on account of their low toxicity, biocompatibility, and ease of formulation scale-up. This review highlights the advances of the last decade in lipid-based codelivery systems focusing on the codelivery of drug–drug, drug–nucleic acid, nucleic acid–nucleic acid, and protein therapeutic-based combinations for targeted therapy in cancer and inflammatory diseases.

Original languageEnglish (US)
Article number2202400
JournalAdvanced Healthcare Materials
Issue number7
StatePublished - Mar 13 2023


  • cancer
  • codelivery
  • combination therapy
  • inflammatory bowel disease
  • lipid nanoparticles
  • psoriasis

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Pharmaceutical Science


Dive into the research topics of 'Advances in Lipid-Based Codelivery Systems for Cancer and Inflammatory Diseases'. Together they form a unique fingerprint.

Cite this